The Merck Index Online is an encyclopaedic database of chemical substances – an evolution of the printed reference work The Merck Index. While the content has a focus on chemicals and biologicals of ...

Merck KGaA has been working with data analytics ... The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

Entrez is a good example of a useful portal to online medical database because the data are referenced, the site is free of commercial influence, it's run by a government agency with academic ...

Ten Times to Try Telehealth from Trusted Medical Reference: MerckManuals.com RAHWAY, N.J., September 10, 2024 – Merck Manuals, an authoritative online medical reference, shares advice from experts on ...

Merck (NYSE:MRK) said on Thursday that its investigational coformulation for metastatic non-small cell lung cancer (NSCLC) did not show an improvement in median progression-free survival (PFS ...

From the late 1950s to early 1980s, for example, Merck medical scientist Dr. Maurice Hilleman, considered “the father of modern vaccines,” helped develop over 40 vaccines to protect human and ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

Merck's Keytruda Secures First FDA-Approval For ... showing significant improvement in progression-free survival compared to chemotherapy. Vandana Singh NuCana's Encouraging Data From Resistant ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...